Here's what the stock needs to do on the charts before heading upstream.
Let's check to see if these gains by the biotech can be sustained.
BIIB shares have jumped around 50% in early trading activity Wednesday.
It's time to play defensive as nearly all the economic signs point to a slowing economy, which won't be good for stocks.
After a deal with GlaxoSmithKline, the small-cap antibiotic developer Spero Therapeutics should get a shot as an options play.
Plus, we take looks at Eli Lilly and Raytheon Technologies after positive news developments for both companies.
The charts don't look promising for GDRX.
The charts give us an answer.
I'm bullish long term, but for now, can BMY generate follow-through buying?
TG Therapeutics could see a win with its multiple sclerosis therapy -- and I've got a lesson for traders staying nimble.